Rates of Resistance to Ceftazidime-Avibactam and Ceftolozane-Tazobactam Among Patients Treated for Multidrug-Resistant Pseudomonas aeruginosa Bacteremia or Pneumonia
Clinical Infectious Diseases · 05.02.2025 · 80 (1) · 24-28
DOI: 10.1093/cid/ciae332 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 21.06.2024. Verfasst von Sunish Shah und 10 weiteren Autor:innen. Beteiligte Einrichtung: Antibiotic Management Program, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Ceftazidime, Cephalosporins, Azabicyclo Compounds, Pseudomonas aeruginosa. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, National Institutes of Health.
Abstract (Originalsprache)
Among consecutive patients with multidrug-resistant Pseudomonas aeruginosa bacteremia or pneumonia we found those treated with ceftazidime-avibactam were more likely to develop resistance (defined as ≥4-fold increased MIC) than those treated with ceftolozane-tazobactam (40% vs 10%; P = .002). Ceftazidime-avibactam resistance was associated with new mutations in ampC and efflux regulatory pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Antibiotic Management Program, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
- Department of Pharmacy, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
- Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh Pennsylvania, USA.
- Department of Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA.
- Office of Quality and Clinical Research Innovation, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
ORCID-Profile: Ryan K Shields
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health
Zitieren
APA
Shah, S., Kline, E. G., Haidar, G., Squires, K. M., Pogue, J. M., McCreary, E. K., Ludwig, J., Clarke, L. G., Stellfox, M., Van Tyne, D., & Shields, R. K. (2025). Rates of Resistance to Ceftazidime-Avibactam and Ceftolozane-Tazobactam Among Patients Treated for Multidrug-Resistant Pseudomonas aeruginosa Bacteremia or Pneumonia. Clinical Infectious Diseases, 80(1), 24-28. https://doi.org/10.1093/cid/ciae332
Vancouver
Shah S, Kline EG, Haidar G, Squires KM, Pogue JM, McCreary EK, et al. Rates of Resistance to Ceftazidime-Avibactam and Ceftolozane-Tazobactam Among Patients Treated for Multidrug-Resistant Pseudomonas aeruginosa Bacteremia or Pneumonia. Clinical Infectious Diseases. 2025;80(1):24-28. doi:10.1093/cid/ciae332
BibTeX
@article{Shah2025,
author = {Shah, Sunish and Kline, Ellen G and Haidar, Ghady and Squires, Kevin M and Pogue, Jason M and McCreary, Erin K and Ludwig, Justin and Clarke, Lloyd G and Stellfox, Madison and Van Tyne, Daria and Shields, Ryan K},
title = {Rates of Resistance to Ceftazidime-Avibactam and Ceftolozane-Tazobactam Among Patients Treated for Multidrug-Resistant Pseudomonas aeruginosa Bacteremia or Pneumonia},
journal = {Clinical Infectious Diseases},
year = {2025},
volume = {80},
number = {1},
pages = {24--28},
doi = {10.1093/cid/ciae332}
}
EUVIMED